Cover
KEYTRUDA
KEYTRUDA 2
KEYTRUDA 3
KEYTRUDA 4
KEYTRUDA 5
KEYTRUDA 6
KEYTRUDA 7
LUGPA
JELMYTO
JELMYTO 2
Pfizer Oncology
Pfizer Oncology 2
Leadership & Editorial Staff
Contents
LUGPA 2025
Letter From the President of LUGPA
PARP Resource Guide
LUGPA News
Correction
IsoPSA
Advances in Radical Prostatectomy: A Narrative Review
Darolutamide for the Management of Metastatic Hormone- Sensitive Prostate Cancer: A Urologist-Oncologist Perspective
Recent Advances in Managing Pediatric Neurogenic Bladder due to Spina Bifida
Incorporation of IsoPSA Into Clinical Practice in the Management of Elevated Prostate- Specific Antigen Based on Current Guidelines
Response to Targeted Therapy and Checkpoint Inhibition in a Patient With Mucinous Tubular and Spindle Cell Carcinoma: A Case Report and Literature Review
Cipla
Immune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical Trials
The Business of Independent Urologic Medicine: Caring for Patients While Operating a Business in a Post–COVID-19 Era of Private Practice
The Specialty Networks Localized to High- Risk Biochemically Recurrent Prostate Cancer Patient Playbook
Localized to High-Risk/Biochemically Recurrent Prostate Cancer
Meet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate Cancer
PPS Analytics
WELIREG
WELIREG 2
WELIREG 3
WELIREG 4
WELIREG 5
WELIREG 6
Pfizer Urology Oncology